Pivotal Therapeutics Exhibiting at the American Heart Association Scientific Sessions 2012
WOODBRIDGE, ON, Nov. 5, 2012 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular disease and overall health, is pleased to announce that the company is exhibiting at the American Heart Associations (AHA) Scientific Sessions 2012 booth #906 in Los Angeles, California until November 7, 2012. The AHA attracts over 20,000 scientists and healthcare professionals from 110 countries and is the largest gathering devoted to the science of cardiovascular disease and stroke and the care of patients with these diseases.
"VASCAZEN® was introduced last year at the AHA and physicians appreciate that by correcting an Omega-3 deficiency you are able to address a broader range of cardiovascular risk factors than current prescription products on the market," said Dr. George Jackowski, Chief Scientific Officer. "Physicians are showing great interest in VASCAZEN® and are excited that it is available to prescribe to their cardiovascular patients."
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only Medical Food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications.
VASCAZEN® is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected by a series of both issued and pending U.S. and foreign patents and commercialized as a prescription only Medical Food in the U.S. This unique formulation will provide the cornerstone upon which a family of cutting edge combination products, with efficacy across a broad spectrum of cardiac care, will be commercialized.
OMAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation commercialized for sale and distribution in Canada for the maintenance of good health through elevating Omega-3 fatty acid levels. The unique formulation and dosage will be available to patients and consumers who realize the health benefits of Omega-3 supplementation with a quality product.
The information contained in this document is as of November 5, 2012. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSNX listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.
More by this Source
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
Mar 10, 2014, 09:40 ET
Pivotal Therapeutics cierra financiación
Mar 04, 2014, 13:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.